Last checked at 2 Sep 2022 11:01
ReNeuron Group plc
("ReNeuron" or "the Group")
Share Purchase by a Director
ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, announces that Iain Ross, Chairman of the Company, has today purchased 100,000 of the Company's ordinary shares of 1p each ("Ordinary Shares").
Name | Title | Number of Ordinary Shares purchased | Resulting beneficial interest in the Company's Ordinary Shares | Percentage of Company's Total Voting Rights |
Iain Ross | Chairman | 100,000 | 100,000 | 0.175% |
ENDS
Enquiries:
ReNeuron | www.reneuron.com/investors | |
Iain Ross, Chairman | Via Walbrook PR | |
Catherine Isted, Chief Executive Officer | ||
Liberum Capital Limited (NOMAD and Joint Broker) Phil Walker (Investment Banking) Richard Lindley (Investment Banking) Ben Cryer (Investment Banking) | +44 (0)20 3110 2000
| |
Allenby Capital Limited (Joint Broker) | +44 (0)20 3328 5656 | |
James Reeve/George Payne (Corporate Finance) | ||
Stefano Aquilino (Sales & Corporate Broking) | ||
Walbrook PR (Media & Investor Relations) | +44 (0)20 7933 8780 or reneuron@walbrookpr.com | |
Paul McManus | +44 (0)7980 541 893 | |
About ReNeuron
ReNeuron is a UK based leader in proprietary stem cell derived exosome technologies, harnessing its unique stem cell technologies to develop 'off the shelf' treatments for diseases with significant unmet needs.
ReNeuron's stem cell derived proprietary exosome technology platform offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. The Group has a growing number of partner collaborations with Global Pharma, Biotech and academic partners in this fast-expanding area of scientific and commercial interest. ReNeuron also has the ability, through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
The Group has out-licenced its CTX Programme for stroke disability and hRPC programme in retinitis pigmentosa to Fosun in China and is looking to out-license both of these programmes in other territories.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
(Disclosure in relation to ordinary shares purchased by Directors and PDMRs)
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||||||
a) | Name | Iain Gladstone Ross | ||||||||
2 | Reason for the notification | |||||||||
a) | Position/status | Chairman and Director | ||||||||
b) | Initial notification /Amendment | Initial notification | ||||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | ReNeuron Group plc | ||||||||
b) | LEI | 2138003TU12CQ5TZO137 | ||||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares 1p RENE - GB00BF5G6K95 | ||||||||
b) | Nature of the transaction | Acquisition of ordinary shares | ||||||||
c) | Price(s) and volume(s)
|
| ||||||||
d)
| Aggregated information | 100,000 ordinary shares at an average price of 27.005p at a total value of £27,005 | ||||||||
e) | Date of the transaction | 02 September 2022 | ||||||||
f) | Place of the transaction | London Stock Exchange AIM Market | ||||||||